Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@ShortShitStocks Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1266679494611361792.png) @ShortShitStocks AustinB

AustinB posts on X about $dcth, $320m, $100m, profitable the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::1266679494611361792/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1266679494611361792/c:line/m:interactions.svg)

- X Week XXXXX +3,928%
- X Month XXXXXX +574%
- X Months XXXXXX -XX%
- X Year XXXXXX +72%

### Mentions: X [#](/creator/twitter::1266679494611361792/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1266679494611361792/c:line/m:posts_active.svg)

- X Week X +25%
- X Month X +800%
- X Months XX -XX%
- X Year XX +30%

### Followers: XXX [#](/creator/twitter::1266679494611361792/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1266679494611361792/c:line/m:followers.svg)

- X Week XXX +14%
- X Month XXX +16%
- X Months XXX +35%
- X Year XXX +16%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1266679494611361792/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1266679494611361792/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1266679494611361792/influence)
---

**Social category influence**
[finance](/list/finance)  XXXX%

**Social topic influence**
[$dcth](/topic/$dcth) 5.88%, [$320m](/topic/$320m) 5.88%, [$100m](/topic/$100m) 5.88%, [profitable](/topic/profitable) 5.88%, [accounting](/topic/accounting) 5.88%, [earning](/topic/earning) XXXX%

**Top accounts mentioned or mentioned by**
[@stockblues](/creator/undefined) [@seedy19tron](/creator/undefined) [@jetsonrook](/creator/undefined) [@towiu2](/creator/undefined) [@samubaaa](/creator/undefined) [@gos137819](/creator/undefined) [@drmakaryfda](/creator/undefined) [@megynkelly](/creator/undefined) [@biohazard3737](/creator/undefined) [@bullishtrade47](/creator/undefined) [@yusufhameed](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@georgfeichting2](/creator/undefined) [@sanctuary_bio](/creator/undefined) [@m_zo_zo](/creator/undefined)

**Top assets mentioned**
[Hundred Million (100M)](/topic/$100m)
### Top Social Posts [#](/creator/twitter::1266679494611361792/posts)
---
Top posts by engagements in the last XX hours

"@TOWiU2 FYI my career is in what I can best summarize as atypical-biotech-CMC. Not that you have any reason to trust me but Im not clueless on this topic"  
[X Link](https://x.com/ShortShitStocks/status/1973046710814298139) [@ShortShitStocks](/creator/x/ShortShitStocks) 2025-09-30T15:26Z XXX followers, XX engagements


"$DCTH +25% is not enough. These results are strongly compelling for a new SOC - and as indications expand I expect that to eventually cover the majority of all liver metastases. At Friday close the EV of the company was $320M. -Current annual revenues (4x last Q) $100M -Turning profitable in 2026 -Y/Y revenues doubling -Onboarding new commercial sites at a rapid pace -High barrier to entry even after patent expiry supporting higher valuation multiplier -Clinical trials ongoing to expand to much larger indications *All this before the new compelling clinical data now pushing Hepzato as a new"  
[X Link](https://x.com/ShortShitStocks/status/1979504379058172056) [@ShortShitStocks](/creator/x/ShortShitStocks) 2025-10-18T11:06Z XXX followers, 8011 engagements


"@SamuBaaa Thanks. For some reason I thought that was due to a one-off accounting situation but my memory may be off. Either way the point is the company will be earning a lot more in the near future"  
[X Link](https://x.com/ShortShitStocks/status/1979528931494506727) [@ShortShitStocks](/creator/x/ShortShitStocks) 2025-10-18T12:44Z XXX followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@ShortShitStocks Avatar @ShortShitStocks AustinB

AustinB posts on X about $dcth, $320m, $100m, profitable the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

  • X Week XXXXX +3,928%
  • X Month XXXXXX +574%
  • X Months XXXXXX -XX%
  • X Year XXXXXX +72%

Mentions: X #

Mentions Line Chart

  • X Week X +25%
  • X Month X +800%
  • X Months XX -XX%
  • X Year XX +30%

Followers: XXX #

Followers Line Chart

  • X Week XXX +14%
  • X Month XXX +16%
  • X Months XXX +35%
  • X Year XXX +16%

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #


Social category influence finance XXXX%

Social topic influence $dcth 5.88%, $320m 5.88%, $100m 5.88%, profitable 5.88%, accounting 5.88%, earning XXXX%

Top accounts mentioned or mentioned by @stockblues @seedy19tron @jetsonrook @towiu2 @samubaaa @gos137819 @drmakaryfda @megynkelly @biohazard3737 @bullishtrade47 @yusufhameed @adamfeuerstein @georgfeichting2 @sanctuary_bio @m_zo_zo

Top assets mentioned Hundred Million (100M)

Top Social Posts #


Top posts by engagements in the last XX hours

"@TOWiU2 FYI my career is in what I can best summarize as atypical-biotech-CMC. Not that you have any reason to trust me but Im not clueless on this topic"
X Link @ShortShitStocks 2025-09-30T15:26Z XXX followers, XX engagements

"$DCTH +25% is not enough. These results are strongly compelling for a new SOC - and as indications expand I expect that to eventually cover the majority of all liver metastases. At Friday close the EV of the company was $320M. -Current annual revenues (4x last Q) $100M -Turning profitable in 2026 -Y/Y revenues doubling -Onboarding new commercial sites at a rapid pace -High barrier to entry even after patent expiry supporting higher valuation multiplier -Clinical trials ongoing to expand to much larger indications *All this before the new compelling clinical data now pushing Hepzato as a new"
X Link @ShortShitStocks 2025-10-18T11:06Z XXX followers, 8011 engagements

"@SamuBaaa Thanks. For some reason I thought that was due to a one-off accounting situation but my memory may be off. Either way the point is the company will be earning a lot more in the near future"
X Link @ShortShitStocks 2025-10-18T12:44Z XXX followers, XXX engagements

creator/x::ShortShitStocks
/creator/x::ShortShitStocks